Coronary restenosis and gene therapy

Area of Science:

• Cardiovascular Research
• Gene Therapy
• Biomedical Engineering

Background:

• Coronary restenosis remains a significant limitation following angioplasty.
• Vascular smooth muscle cell proliferation and migration are key contributors to restenosis.
• Current gene transfer methods often fail to achieve therapeutic protein levels in vivo.

Purpose of the Study:

• To evaluate adenovirus-mediated gene therapy for preventing coronary restenosis.
• To compare the efficacy of adenoviral vectors against conventional gene transfer methods.
• To assess the duration and level of gene expression in porcine coronary arteries.

Main Methods:

• Utilized recombinant adenoviruses expressing reporter genes (beta-galactosidase, luciferase).
• Evaluated gene transfer in cultured coronary vascular smooth muscle cells (in vitro).
• Assessed gene transfer efficacy and duration in porcine coronary arteries (in vivo) via percutaneous transluminal gene transfer.

Main Results:

• Adenovirus vectors produced 70- to 240-fold higher reporter protein levels than Lipofectin-DNA complexes in vivo.
• High levels of adenovirus-mediated gene expression persisted for at least 14 days post-catheterization.
• Demonstrated efficient direct gene transfer using adenoviral vectors in a relevant animal model.

Conclusions:

• Adenovirus-mediated gene therapy is a promising strategy for preventing coronary restenosis.
• Adenoviral vectors overcome limitations of conventional gene transfer for achieving therapeutic protein levels.
• Further studies are needed to assess cellular distribution and host immune response to adenovirus vectors.